JP6049700B2 - 肺動脈高血圧の治療におけるｍｉｃｒｏＲＮＡの調節方法 - Google Patents

肺動脈高血圧の治療におけるｍｉｃｒｏＲＮＡの調節方法 Download PDF

Info

Publication number
JP6049700B2
JP6049700B2 JP2014509823A JP2014509823A JP6049700B2 JP 6049700 B2 JP6049700 B2 JP 6049700B2 JP 2014509823 A JP2014509823 A JP 2014509823A JP 2014509823 A JP2014509823 A JP 2014509823A JP 6049700 B2 JP6049700 B2 JP 6049700B2
Authority
JP
Japan
Prior art keywords
mir
mice
pah
inhibitor
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014509823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516027A5 (enrdf_load_stackoverflow
JP2014516027A (ja
Inventor
ベイカー，アンドリュー
マクリーン，マーガレット
マレル，ニコラス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of JP2014516027A publication Critical patent/JP2014516027A/ja
Publication of JP2014516027A5 publication Critical patent/JP2014516027A5/ja
Application granted granted Critical
Publication of JP6049700B2 publication Critical patent/JP6049700B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014509823A 2011-05-09 2012-05-09 肺動脈高血圧の治療におけるｍｉｃｒｏＲＮＡの調節方法 Expired - Fee Related JP6049700B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161484091P 2011-05-09 2011-05-09
US61/484,091 2011-05-09
US201261605376P 2012-03-01 2012-03-01
US61/605,376 2012-03-01
PCT/GB2012/051018 WO2012153135A1 (en) 2011-05-09 2012-05-09 Methods of modulating micrornas in the treatment of pulmonary arterial hypertension

Publications (3)

Publication Number Publication Date
JP2014516027A JP2014516027A (ja) 2014-07-07
JP2014516027A5 JP2014516027A5 (enrdf_load_stackoverflow) 2015-06-11
JP6049700B2 true JP6049700B2 (ja) 2016-12-21

Family

ID=46178572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014509823A Expired - Fee Related JP6049700B2 (ja) 2011-05-09 2012-05-09 肺動脈高血圧の治療におけるｍｉｃｒｏＲＮＡの調節方法

Country Status (11)

Country Link
US (1) US9267134B2 (enrdf_load_stackoverflow)
EP (1) EP2707485B1 (enrdf_load_stackoverflow)
JP (1) JP6049700B2 (enrdf_load_stackoverflow)
KR (1) KR20140037868A (enrdf_load_stackoverflow)
CN (1) CN103814131A (enrdf_load_stackoverflow)
AU (1) AU2012252165A1 (enrdf_load_stackoverflow)
BR (1) BR112013029016A2 (enrdf_load_stackoverflow)
CA (1) CA2835568A1 (enrdf_load_stackoverflow)
CO (1) CO6870004A2 (enrdf_load_stackoverflow)
SG (1) SG194901A1 (enrdf_load_stackoverflow)
WO (1) WO2012153135A1 (enrdf_load_stackoverflow)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6446026B2 (ja) 2013-03-15 2018-12-26 ミラゲン セラピューティクス， インコーポレイテッド 架橋二環式ヌクレオシド
JP6410791B2 (ja) * 2013-03-15 2018-10-24 ミラゲン セラピューティクス， インコーポレイテッド Ｍｉｒ−１４５のロックト核酸阻害剤およびその使用
US9840705B2 (en) * 2013-12-02 2017-12-12 The University Court Of The University Of Glasgow Materials and methods for treatment of pulmonary arterial hypertension
AU2015296037B2 (en) * 2014-08-01 2021-04-29 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
MX2017009110A (es) * 2015-01-13 2017-11-09 Vivus Inc Terapia de combinacion para hipertension pulmonar.
EP3533868A4 (en) * 2016-10-31 2019-12-11 Gifu University DOUBLE-STRUCTURED NUCLEIC ACID MOLECULE AND USE THEREOF
CN119607006A (zh) * 2019-12-09 2025-03-14 艾姆皮瑞克公司 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
WO2022154636A1 (ko) * 2021-01-18 2022-07-21 (주)스템메디텍 Mir 145 억제제를 유효성분으로 포함하는 심근경색증의 치료용 조성물
CN113332306A (zh) * 2021-04-28 2021-09-03 武汉华纪元生物技术开发有限公司 用于治疗肺动脉高血压的microRNA-30a抑制剂及其应用
GB202215974D0 (en) * 2022-10-28 2022-12-14 Imperial College Innovations Ltd Microrna panels for pulmonary hypertension

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
AU7404994A (en) 1993-07-30 1995-02-28 Regents Of The University Of California, The Endocardial infusion catheter
GB9525620D0 (en) 1995-12-15 1996-02-14 Glaxo Group Ltd Chemical compounds
SE9600216D0 (sv) 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
ES2171945T3 (es) 1996-05-31 2002-09-16 C & C Res Lab Derivados aromaticos de amidina que sirven de inhibidores selectivos de la trombina.
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
US6416510B1 (en) 1997-03-13 2002-07-09 Biocardia, Inc. Drug delivery catheters that attach to tissue and methods for their use
US6147109A (en) 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6749617B1 (en) 1997-11-04 2004-06-15 Scimed Life Systems, Inc. Catheter and implants for the delivery of therapeutic agents to tissues
SI20474A (sl) 1998-05-26 2001-08-31 Icn Pharmaceuticals, Inc. Novi nukleozidi, ki imajo bicikličen sladkorni del
EP1117398A2 (en) 1998-09-28 2001-07-25 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7722596B2 (en) 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
US20070203445A1 (en) 2004-02-26 2007-08-30 V-Kardia Pty Ltd Isolating cardiac circulation
JP4819788B2 (ja) 2004-02-26 2011-11-24 オスプレイ メディカル インク． 分離用心循環
WO2006089340A2 (en) 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
EP2671949A1 (en) 2005-12-12 2013-12-11 University Of North Carolina At Chapel Hill Micro-RNA miR-145 that regulate muscle cell proliferation and differentiation
US8741861B2 (en) 2008-03-27 2014-06-03 Vascular Biosciences Methods of novel therapeutic candidate identification through gene expression analysis in vascular-related diseases
WO2010104796A2 (en) 2009-03-09 2010-09-16 The J. David Gladstone Institutes Methods of modulating smooth muscle cell proliferation and differentiation
CN101843632B (zh) * 2009-03-24 2012-07-04 复旦大学附属华山医院 miR-145在制备治疗炎症药物中的应用
CA2765129A1 (en) * 2009-06-08 2010-12-16 Miragen Therapeutics Chemical modification motifs for mirna inhibitors and mimetics
AU2010340062A1 (en) * 2009-12-15 2012-07-12 Board Of Regents, The University Of Texas System Micro-RNA regulation in ischemia and ischemia-reperfusion injury
CN102382824A (zh) 2010-09-01 2012-03-21 中国科学院上海药物研究所 人miR-145反义核酸及其应用

Also Published As

Publication number Publication date
SG194901A1 (en) 2013-12-30
CN103814131A (zh) 2014-05-21
BR112013029016A2 (pt) 2017-01-17
EP2707485B1 (en) 2016-12-14
CO6870004A2 (es) 2014-02-20
JP2014516027A (ja) 2014-07-07
US9267134B2 (en) 2016-02-23
EP2707485A1 (en) 2014-03-19
WO2012153135A1 (en) 2012-11-15
KR20140037868A (ko) 2014-03-27
US20140163086A1 (en) 2014-06-12
AU2012252165A1 (en) 2013-03-21
CA2835568A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
JP6049700B2 (ja) 肺動脈高血圧の治療におけるｍｉｃｒｏＲＮＡの調節方法
US8629119B2 (en) Dual targeting of MIR-208 and MIR-499 in the treatment of cardiac disorders
CN101563458A (zh) 治疗肌肉和心血管病症的组合物和方法
JP2011513238A (ja) 平滑筋の増殖および分化を調節するマイクロｒｎａならびにこれらの使用
JP2015525081A (ja) マイクロｒｎａのｍｉｒ−１５ファミリーの阻害剤
JP2014504857A (ja) ロックドヌクレオチドを含むｍｉｃｒｏＲＮＡ阻害剤
US20120282326A1 (en) Compositions and methods related to mirna in diabetic conditions
WO2010120969A1 (en) Targeting of the mir-30 family and let-7 family as a treatment for heart disease
US20160208258A1 (en) Mir-92 inhibitors and uses thereof
JP7646359B2 (ja) ｍｉＲ－１８１阻害剤及びその使用
JP6410791B2 (ja) Ｍｉｒ−１４５のロックト核酸阻害剤およびその使用
JP6430945B2 (ja) Ｒｎａ活性及び血管透過性の調節
WO2010129950A1 (en) Micro-rna that regulates cardiac remodeling

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161122

R150 Certificate of patent or registration of utility model

Ref document number: 6049700

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees